- Home
- MRSN vs AGD Comparison
MRSN vs AGD Comparison
Compare MRSN & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- AGD
- Stock Information
- Founded
- MRSN 2001
- AGD 2006
- Country
- MRSN United States
- AGD United Kingdom
- Employees
- MRSN N/A
- AGD N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- AGD Trusts Except Educational Religious and Charitable
- Sector
- MRSN Health Care
- AGD Finance
- Exchange
- MRSN Nasdaq
- AGD Nasdaq
- Market Cap
- MRSN 230.0M
- AGD 253.4M
- IPO Year
- MRSN 2017
- AGD N/A
- Fundamental
- Price
- MRSN $2.21
- AGD $10.07
- Analyst Decision
- MRSN Buy
- AGD
- Analyst Count
- MRSN 6
- AGD 0
- Target Price
- MRSN $6.00
- AGD N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- AGD 61.2K
- Earning Date
- MRSN 11-13-2024
- AGD 01-01-0001
- Dividend Yield
- MRSN N/A
- AGD 8.13%
- EPS Growth
- MRSN N/A
- AGD N/A
- EPS
- MRSN N/A
- AGD N/A
- Revenue
- MRSN $34,837,000.00
- AGD N/A
- Revenue This Year
- MRSN N/A
- AGD N/A
- Revenue Next Year
- MRSN $7.15
- AGD N/A
- P/E Ratio
- MRSN N/A
- AGD N/A
- Revenue Growth
- MRSN N/A
- AGD N/A
- 52 Week Low
- MRSN $1.22
- AGD $8.20
- 52 Week High
- MRSN $6.28
- AGD $9.78
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- AGD 35.22
- Support Level
- MRSN $2.12
- AGD $10.30
- Resistance Level
- MRSN $2.83
- AGD $10.42
- Average True Range (ATR)
- MRSN 0.24
- AGD 0.12
- MACD
- MRSN 0.03
- AGD -0.02
- Stochastic Oscillator
- MRSN 39.81
- AGD 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current dividend income. The Fund also focuses on the long-term growth of capital as a secondary investment objective.